The global idiopathic pulmonary fibrosis treatment market size reached US$ 3,848.3 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 6,980.4 Million by 2032, exhibiting a growth rate (CAGR) of 6.6% during 2024-2032. More Info:- https://www.imarcgroup.com/idiopathic-pulmonary-fibrosis-treatment-market

1. Global Idiopathic
Pulmonary Fibrosis
Treatment Market
Research and Forecast
Report 2024-2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved

2. About IMARC Group
International Market Analysis Research and Consulting Group is a leading adviser on management
strategy and market research worldwide. We partner with clients in all regions and industry
verticals to identify their highest-value opportunities, address their most critical challenges, and
transform their businesses.
IMARC’s information products include major market, scientific, economic and technological
developments for business leaders in pharmaceutical, industrial, and high technology
organizations. Market forecasts and industry analysis for biotechnology, advanced materials,
chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods
are at the top of the company’s expertise.
IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and
markets with close cooperation at all levels of the client organization. This ensures that our clients
achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting
results.

3. Report Highlight
and Description
According to the latest report by IMARC Group, titled "Idiopathic Pulmonary
Fibrosis Treatment Market: Global Industry Trends, Share, Size, Growth,
Opportunity and Forecast 2024-2032," the global idiopathic pulmonary
fibrosis treatment market size reached US$ 3,848.3 Million in 2023.
Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease that causes
scarring of the lungs, reducing their oxygen delivering capacity. The chronic
lung disease is progressive and irreversible in nature as it continuously
impacts the functioning of the lungs. It causes difficulty in breathing and does
not provide sufficient oxygen to different body parts.
IPF can be diagnosed through chest imaging studies, lung biopsies, pulmonary
function tests, and antibody tests. The treatment includes nintedanib and
pirfenidone-based drugs that aid in lung functioning and minimize the risk of
acute respiratory deterioration. They are also offered along with oxygen
therapy and palliative care, which improve the chances of recovery and provide
comfort to the patient.
Request for a PDF sample of this report:
https://www.imarcgroup.com/idiopathic -pulmonary-fibrosis-treatment-
market/requestsample

4. Report Description
Global Idiopathic Pulmonary Fibrosis Treatment Market Trends:
The market is primarily driven by the rising geriatric population, which is susceptible to lung disorders. Aging is
considered the greatest risk factor for the development of IPF. Moreover, the growing prevalence of fibrotic
diseases, owing to changing lifestyles and heavy consumption of nicotine products like cigarettes is also
propelling the demand for IPF treatment.
Besides this, major healthcare companies are extensively investing in the development and commercialization of
novel drugs, especially in emerging economies, which is fueling the growth of the market. The rising health
consciousness among individuals regarding effective management strategies is also creating a positive outlook for
the market. Furthermore, increasing healthcare expenditures and improving infrastructure are also facilitating the
market growth.
Looking forward, the market value is expected to reach US$ 6,980.4 Million by 2032, exhibiting a CAGR of
6.6% during the forecast period (2024-2032).
View Report TOC, Figures and Tables: https://www.imarcgroup.com/idiopathic-pulmonary-fibrosis-
treatment-market

5. Report
Segmentation
Breakup by Drug Class:
• MAPK Inhibitors
• Tyrosine Inhibitors
• Autotaxin Inhibitors
Breakup by End User:
• Hospitals
• Long-term Care Facilities
• Others
Breakup by Region:
• North America
• Asia-Pacific
• Europe
• Latin America
• Middle East and Africa

6. Competitive
Landscape with
Key Players
• AdAlta Pty Ltd.
• Angion Biomedica Corp.
• Boehringer Ingelheim International GmbH (C. H.
Boehringer Sohn AG & Co. KG)
• Bristol-Myers Squibb Company
• Cipla Inc.
• F. Hoffmann-La Roche AG (Roche Holding AG)
• Fibrogen Inc.
• Galapagos NV
• Liminal BioSciences Inc.
• Medicinova Inc.
• Merck & Co. Inc.
• Novartis AG
• Vectura Group Plc.

7. Key Questions
Answered in
the Report
How has the global idiopathic pulmonary fibrosis treatment market
performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global idiopathic
pulmonary fibrosis treatment market?
What are the key regional markets?
What is the breakup of the market based on the drug class?
What is the breakup of the market based on the end user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global idiopathic pulmonary fibrosis treatment
market and who are the key players?
What is the degree of competition in the industry?

8. Table of
Contents
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Idiopathic Pulmonary Fibrosis Treatment
Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Drug Class
6.1 MAPK Inhibitors
6.1.1 Mark et Trends
6.1.2 Mark et Forecast
6.2 Tyrosine Inhibitors
6.2.1 Mark et Trends
6.2.2 Mark et Forecast
6.3 Autotaxin Inhibitors
6.3.1 Mark et Trends
6.3.2 Mark et Forecast
7 Mark et Breakup by End User

9. Table of
Contents
7.1 Hospitals
7.1.1 Mark et Trends
7.1.2 Mark et Forecast
7.2 Long-term Care Facilities
7.2.1 Mark et Trends
7.2.2 Mark et Forecast
7.3 Others
7.3.1 Mark et Trends
7.3.2 Mark et Forecast
8 Market Breakup by Region
8.1 North America
8.1.1 United States
8.1.1.1 Mark et Trends
8.1.1.2 Mark et Forecast
8.1.2 Canada
8.1.2.1 Mark et Trends
8.1.2.2 Mark et Forecast
8.2 Asia Pacif ic
8.2.1 China
8.2.1.1 Mark et Trends
8.2.1.2 Mark et Forecast
8.2.2 Japan
8.2.2.1 Mark et Trends
8.2.2.2 Mark et Forecast
8.2.3 India
8.2.3.1 Mark et Trends
8.2.3.2 Mark et Forecast
8.2.4 South Korea
8.2.4.1 Mark et Trends
8.2.4.2 Mark et Forecast
For more information, visit :
https://www.imarcgroup.com/idiopathic -pulmonary-fibrosis-
treatment-market/toc

10. Partial List of Clients

11. Partial List of Clients

12. Disclaimer
© 2024 IMARC All Rights Reserved
This Publication and all it’s contents unless otherwise mentioned are copyrighted in the
name of International Market Analysis Research and Consulting (IMARC). No part of this
publication may be reproduced, repackaged, redistributed or resold in whole or in any part.
The publication may also not be used in any form or by and means graphic electronic or
mechanical, including photocopying, recording, taping or by information storage or retrieval,
or by any other form, without the express consent of International Market Analysis Research
and Consulting (IMARC).
Disclaimer: All contents and data of this publication, including forecasts, data analysis and
opinion have been based on information and sources believed to be accurate and reliable at
the time of publishing. International Market Analysis Research and Consulting makes no
representation of warranty of any kind as to the accuracy or completeness of any Information
provided. IMARC accepts no liability whatsoever for any loss or damage resulting from
opinion, errors or inaccuracies if any found this publication.
IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of
International Market Analysis Research and Consulting. All other trademarks used in this
publication are registered trademarks of their respective companies.

13. Contact Us
Visit us at :
https://www.imarcgroup.com
+1-631-791-1145
sales@imarcgroup.com
Stay With Us: